MDXG MiMedx Group Inc

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

Date	Price Target	Rating	Analyst
7/2/2024	$11.00	Overweight	Cantor Fitzgerald
3/7/2024	$12.00	Buy	Lake Street
10/27/2023	$12.00	Buy	Craig Hallum
10/13/2022	$7.00	Buy	Mizuho
9/14/2021	$20.00 → $8.50	Buy	HC Wainwright & Co.
7/26/2021	$23.00	Outperform	Northland Capital

MiMedx Group Inc

Recent Analyst Ratings for MiMedx Group Inc

MiMedx Group Inc Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Newton Todd was granted 28,609 shares, increasing direct ownership by 7% to 412,771 units (SEC Form 4)

Director Behrens M Kathleen was granted 28,609 shares, increasing direct ownership by 16% to 212,771 units (SEC Form 4)

Director Bierman James L was granted 28,609 shares, increasing direct ownership by 16% to 212,771 units (SEC Form 4)

Director Hawkins William A was granted 28,609 shares, increasing direct ownership by 16% to 204,018 units (SEC Form 4)

Director Laurencin Cato T was granted 28,609 shares, increasing direct ownership by 19% to 181,923 units (SEC Form 4)

Director Olson Tiffany was granted 28,609 shares, increasing direct ownership by 99% to 57,597 units (SEC Form 4)

Director Puhy Dorothy E was granted 28,609 shares, increasing direct ownership by 99% to 57,597 units (SEC Form 4)

General Counsel and CAO Hulse William Frank Iv covered exercise/tax liability with 8,877 shares, decreasing direct ownership by 2% to 413,549 units (SEC Form 4)

Chief Executive Officer Capper Joseph H bought $1,268,000 worth of shares (200,000 units at $6.34), increasing direct ownership by 61% to 529,530 units (SEC Form 4)

General Counsel and CAO Hulse William Frank Iv covered exercise/tax liability with 8,876 shares, decreasing direct ownership by 2% to 422,426 units (SEC Form 4)

MiMedx Group Inc Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Capper Joseph H bought $1,268,000 worth of shares (200,000 units at $6.34), increasing direct ownership by 61% to 529,530 units (SEC Form 4)

Doug Rice bought $35,786 worth of shares (5,000 units at $7.16), increasing direct ownership by 5% to 102,200 units (SEC Form 4)